Blood tests for HPV DNA in patients with HPV-positive throat cancer
Tests blood for HPV DNA in adults with HPV-positive throat cancer during treatment and follow-up.
Plain-language title generated from the registry record
Registry title: Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
Key facts
- Where
- Lund, SwedenSee the site
Where in Sweden
- Dept. of ORL-HNSLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Skane
- Trial code
- NCT05649865
- Record updated
- 8 June 2023
- Original description
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV.Read full original descriptionShow less
Analysis of HPV DNA in Plasma in Patients With HPV-positive Oropharyngeal Squamous Cell Carcinoma - a Prospective Study of HPV DNA Levels for Treatment Response and Surveillance
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV.
The main question to answer is if the presence of HPV DNA in the blood one month after the treatment is useful in detecting remaining tumour or relapse within two years after treatment.
The participants will be asked to provide blood tests:
1. before treatment 2. weekly during the treatment 3. on all scheduled follow-up appointments 4. on all unplanned appointments where a relapse is suspected
Inclusion: Only patients with an HPV-positive primary tumour will eventually be eligible for inclusion; Non-detectable ctHPVDNA at diagnosis will not be a reason for exclusion; Age >18 years; Able to give informed consent; The patient will be treated with curative intent.
Exclusion: Patients with a short life expectancy, psychiatric or addictive disorders, or other medical conditions which might impair patient compliance may be excluded at the discretion of the investigator.